Affordable Access

Publisher Website

Microdose follicular flare: a viable alternative for normal-responding patients undergoing in vitro fertilization?

Authors
Journal
Fertility and Sterility
0015-0282
Publisher
Elsevier
Publication Date
Volume
91
Issue
1
Identifiers
DOI: 10.1016/j.fertnstert.2007.11.018
Keywords
  • Leuprolide Acetate
  • Microdose Follicular Flare
  • Gnrh Agonist
  • Assisted Reproductive Technology

Abstract

Objective To compare cycle outcomes among normal-responding patients ≤30 years old receiving microdose follicular flare (MDF) and long-luteal agonist (LL). Design Retrospective cohort study. Setting Military-based assisted reproductive technology (ART) center. Patient(s) First autologous ART cycles among 499 women ≤30 years old from January 1999 to December 2005. Intervention(s) After oral contraceptive pill (OCP) administration before cycle start, patients were nonrandomly assigned to either LL or MDF for LH surge suppression. Patients in the LL group received 1 mg/day leuprolide acetate (LA) on cycle day 21, which was reduced to 0.25 mg/day 10–14 days later. Patients in the MDF group received LA (40 μg twice a day) beginning 3 days after discontinuing OCPs. Both groups received a combination of hMG and recombinant FSH. Main Outcome Measure(s) Primary outcomes were implantation, clinical pregnancy, and live-birth rates; in-cycle variables included peak E 2, oocytes retrieved, oocyte maturity, and fertilization rate. Result(s) Multivariable models controlling for confounding by treatment indication found no significant differences between groups in implantation (MDF, 36%; LL, 38%), clinical pregnancy (MDF, 53%; LL, 56%), and live-birth rates (MDF, 47%; LL, 50%). No differences were observed in peak E 2, oocytes retrieved, oocyte maturity, fertilization rate, or embryos transferred. Conclusion(s) MDF use among normal-responding ART patients produced no differences in cycle outcome when compared with LL. Therefore, MDF may be a viable alternative for normal-responding patients.

There are no comments yet on this publication. Be the first to share your thoughts.